Syntara Limited · ASX:SNT
Syntara — Investor Presentation (February 2026)
9 slides from Syntara's investor presentation, Feb 3, 2026
Slide 1: 2026 – Outlook Webinar
For personal use only 2026 – Outlook Webinar Gary Phillips, CEO 3 February 2026
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT For personal use only This document contains These forward-looking forward-looking statements, statements are not guarantees including statements or predictions of future results, concerning Syntara’s future levels of performance, and financial position, plans, and the invo
Slide 3: Participants
2026 – Outlook Webinar Participants For personal use only Hashan De Silva Gary Phillips Non Executive CEO Director • Experienced life sciences • More than 30 years investment professional with of operational management extensive knowledge of the biotech, experience in the pharmaceutical and medical
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only Australian-founded Backed by Multiple shots on Funded into 2027 with clinical stage specialist healthcare goal from additional near term data to drive drug developer. investors – Phase 2, Phase 1 and value over the next 47% institutional. preclinical asset
Slide 5: Shareholders & Cash
SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share Price & Volume – YTD Share price – 02 February 2026 $0.032 For personal use only Close 0.1 Market cap A$52.2m 0.08 Cash balance – 31 December 2025 A$12.3m 0.06 Enterprise value A$39.9m 0.04 0.02 Institutional Ownership 30 Sept 25 0 Volume D&
Slide 6: Investment highlights as we head into 2026
Investment highlights as we head into 2026 • Lead asset amsulostat continues to build momentum o Amsulostat clinical and preclinical data presented at American Society of Hematology (ASH) Annual Meeting in Orlando For personal use only o Second myelodysplastic syndrome (MDS) study initiated with lau
Slide 7: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 NEWS FLOW HEALTHY H1 2026 H2 2026 PATIENTS For personal use only PARTICIPANTS FDA approved development plan Myelofibrosis and partner engagement High Risk MDS Interim safety and Phase 2 initiation AZAL
Slide 8: For personal use only
For personal use only
Slide 9: For personal use only
For personal use only Syntara Limited ABN 75 082 811 630 Gary Phillips Chief Executive Officer www.syntaraTX.com.au gary.phillips@syntaraTX.com.au